Validated Laboratory Standard
Revision 1 · Lyophilized Solid Powder
Gastric Pentadecapeptide Laboratory Protocol & In-Vitro Angiogenesis Standard. Formulated for in-vitro research and laboratory analytical validation.
Gastric Pentadecapeptide Laboratory Protocol & In-Vitro Angiogenesis Standard. Formulated for in-vitro research and laboratory analytical validation.
What it is: BPC-157 (Body Protection Compound-157) is a peptide composed of 15 amino acids, originally discovered in natural gastric digestive juices where it protects stomach tissue from acid and enzymes.
How it works: In laboratory models, BPC-157 stimulates the formation of fresh microvascular blood vessels (angiogenesis) by activating early growth response-1 (egr-1) and VEGF receptor pathways. It also activates nitric oxide (eNOS) production to improve local blood flow, while upregulating collagen synthesis and cell migration directly at damaged tissue sites.
Why researchers study it: Studied extensively for accelerating tendon, ligament, muscle, and gut lining healing, reducing systemic inflammation, and protecting gastrointestinal integrity from injury and ulceration.
Analysis of VEGF Upregulation, FAK-Paxillin Focal Adhesion Phosphorylation, Gastric Cytoprotection, and Tenocyte Collagen Fibrillogenesis.
BPC-157 (molecular formula C62H98N16O22, exact monoisotopic molecular weight 1419.53 Da) is a 15-amino acid synthetic peptide with the primary sequence: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. The peptide sequence corresponds to residues 116-130 of the 40 kDa human gastric juice Body Protection Compound.
A notable biophysical characteristic of BPC-157 is its intrinsic thermodynamic and enzymatic stability. Unlike standard linear peptides that undergo rapid degradation in gastric acid or plasma proteases within minutes, BPC-157 remains structurally intact in simulated gastric juice (0.1 N HCl, pH 1.0 with pepsin) for over 24 hours at 37°C without loss of biological potency. This extreme stability is attributed to a compact proline-rich polyproline II (PPII) helical turn centered around the Pro3-Pro4-Pro5 triad, which sterically restricts access of endopeptidases to the peptide backbone.
High-performance liquid chromatography (HPLC) and electrospray ionization mass spectrometry (ESI-MS) indicate that standard solid lyophilized cakes remain stable at ambient room temperature (20°C–25°C) for over 60 days without spontaneous racemization or hydrolytic deamidation.
BPC-157 exerts potent angiogenic actions that differ fundamentally from uncontrolled growth factor administration. In human umbilical vein endothelial cells (HUVECs) and aortic explant cultures, BPC-157 stimulates capillary tube formation and endothelial sprouting at concentrations ranging from 10 pg/mL to 10 ng/mL.
This angiogenic cascade is initiated by the transcriptional upregulation of early growth response-1 (egr-1), a master zinc-finger transcription factor that coordinates vascular remodeling genes. Concurrently, BPC-157 promotes internal phosphorylation of vascular endothelial growth factor receptor 2 (VEGFR2) via an alternative, non-VEGF-ligand-dependent transactivation mechanism, circumventing the risk of pathological systemic neovascularization.
Crucially, BPC-157 modulates the endogenous nitric oxide (NO) synthase system: it upregulates endothelial nitric oxide synthase (eNOS), ensuring microvascular vasodilation and tissue perfusion, while simultaneously suppressing overactivation of inducible nitric oxide synthase (iNOS), thereby preventing toxic peroxynitrite radical accumulation in inflamed tissue.
In orthopedic tissue healing, tendon and ligament injuries present clinical challenges due to poor vascularity and low cellular mitotic rates. Chang et al. (J Appl Physiol 2011) demonstrated that BPC-157 promotes tendon outgrowth, cell survival, and cell migration in rat Achilles tenocyte explants.
Mechanistically, BPC-157 induces robust phosphorylation of both focal adhesion kinase (FAK) at Tyr397 and paxillin at Tyr118. This FAK-paxillin focal adhesion complex governs the cytoskeletal actin rearrangements required for lamellipodia extension and directional cellular migration into mechanical lesions.
In vivo biomechanical testing of transected rat Achilles tendons treated with BPC-157 revealed a 70% increase in tensile load-to-failure at day 14 compared to untreated controls. Histological analysis confirmed dense, parallel organization of Type I collagen fibrils, reduced granulation scarring, and restoration of functional fibrocartilage enthesis at the tendon-to-bone junction.
The seminal research by Sikiric and colleagues (Curr Pharm Des 2018) established BPC-157 as a prototypical organoprotective agent. In preclinical models of gastrointestinal pathology, BPC-157 accelerates the healing of severe gastric and duodenal ulcers induced by non-steroidal anti-inflammatory drugs (NSAIDs such as indomethacin, aspirin, and diclofenac), alcohol toxicity, and stress.
Beyond the upper gastrointestinal tract, BPC-157 demonstrates efficacy in lower bowel pathologies: it promotes the closure of enterocutaneous, colocutaneous, and gastrocutaneous fistulas in animal models, and attenuates colitis in dextran sulfate sodium (DSS) and trinitrobenzene sulfonic acid (TNBS) models of inflammatory bowel disease (IBD).
The cytoprotective mechanism involves the maintenance of mucosal blood flow, restoration of the endothelial barrier, and modulation of inflammatory cytokine cascades—downregulating TNF-alpha, IL-6, and myeloperoxidase (MPO) while promoting mucosal cell proliferation.
In laboratory research, BPC-157 is synthesized as a lyophilized white powder, typically provided as the acetate or stable arginate salt. The monoisotopic mass is 1419.53 Da.
Stoichiometric reconstitution protocol: for a standard 5.0 mg vial, the addition of 2.0 mL of Bacteriostatic Water USP (0.9% benzyl alcohol) yields a clean 2.5 mg/mL (2,500 mcg/mL) working stock. For lower concentration research models, adding 5.0 mL diluent yields 1.0 mg/mL (1,000 mcg/mL).
Syringe unit translation on a standard U-100 syringe (100 units = 1.0 mL; 1 unit = 0.01 mL): at 2.5 mg/mL, 10 units delivers 250 mcg net peptide; 20 units delivers 500 mcg. At 1.0 mg/mL, 25 units delivers 250 mcg net peptide. Diluent should be slowly injected along the vial wall. Complete dissolution occurs in under 30 seconds, yielding an optically transparent solution with neutral pH (6.5–7.2).
Storage parameters: Lyophilized solid vials maintain stable integrity at -20°C for up to 36 months, or 2°C–8°C for 18 months. Reconstituted aqueous solution with 0.9% benzyl alcohol must be stored refrigerated at 2°C–8°C and protected from direct sunlight, maintaining potency for up to 28 days. Avoid freeze-thaw cycles of the reconstituted solution.
BPC-157 displays an exceptional preclinical safety profile. Across extensive animal toxicity studies conducted over three decades, no median lethal dose (LD50) could be established even at astronomical doses up to 10 mg/kg administered parenterally.
Genotoxicity assays (Ames bacterial reverse mutation test, in vitro chromosomal aberration assays, and in vivo micronucleus tests in rodent bone marrow) demonstrated no mutagenic or clastogenic activity. Systemic organ histopathology following subchronic 90-day administration revealed no adverse changes in liver, kidney, cardiac, or neuronal tissues.
Importantly, despite its pro-angiogenic actions in damaged tissue, BPC-157 does not promote tumor angiogenesis or accelerate malignant cell proliferation in benchmark oncological cell lines; its angiogenic induction is strictly dependent on tissue injury signals and normalized cellular microenvironments.
Target Solvent
Bacteriostatic Water USP (0.9% Benzyl Alcohol)
Clear, colorless aqueous solution once dissolved. Inspect against a dark backdrop for optical clarity before experimental use. Aseptic mixing with Bacteriostatic Water is required; gently swirl rather than shake to protect peptide bonds, and refrigerate between 2°C–8°C.
Diluent Ratio
2 mL per 10 mg (5 mg/mL)
Direct the needle bevel gently against the inside glass vial wall. Allow the vacuum to smoothly draw diluent into the vial without vigorous bubbling. Swirl in a continuous horizontal circular motion for 45–60 seconds. Do not invert or shake to prevent peptide shearing.
Lyophilized Storage
-20°C in dry desiccator protected from moisture and light (24 months shelf-life)
Desiccated and protected from thermal spikes
Liquid Stability
2°C–8°C refrigerated; use within 28 days for optimal molecular stability
Refrigerated and light-protected
Pharmacokinetics / Half-Life
~4–6 Hours (Systemic peptide stability; localized extracellular retention ~24h)
Typical protocol duration: 4 to 6 Weeks per analytical research block; Washout: 2 to 4 Weeks between experimental cycles
| Standard Compound Mass | 5 mg active per vial |
| Recommended Diluent | Bacteriostatic Water USP (0.9% Benzyl Alcohol) |
| Diluent Volume Added | 2.0 mL |
| Resulting Concentration | 2.5 mg/mL |
| Syringe Volumetric Scale | U-100 Syringe (100 units = 1.0 mL | 1 unit = 25.0 mcg (0.01 mL)) |
| Handling Rule | Clear, colorless aqueous solution once dissolved. Inspect against a dark backdrop for optical clarity before experimental use. Aseptic mixing with Bacteriostatic Water is required; gently swirl rather than shake to protect peptide bonds, and refrigerate between 2°C–8°C. |
Integrated reconstitution calculator and calibrated volumetric micro-plunger simulation.
Benchmark protocols from peer-reviewed clinical trials & institutional investigational programs.
| Escalation Stage & Phase | Target Dose | U-100 Mark (10mg / 2.0mL) | Cadence | Syringe Sync |
|---|---|---|---|---|
| In-Vitro Assay Titration Schedule (Days 1–7) | 250 mcg | 5.0 Units(0.05 mL) | 1x Daily | |
| In-Vitro Assay Titration Schedule (Weeks 2–5) | 500 mcg | 10.0 Units(0.10 mL) | 1x Daily | |
| In-Vitro Assay Titration Schedule (Week 6+) | 0 mcg | 0.0 Units(0.00 mL) | 1x Daily |
| Research Dose | Volume (mL) | U-100 Syringe Graduation Mark |
|---|---|---|
| 100 mcg (Micro Calibration) | 0.020 mL | 2 Units 2.0 units (0.02 mL) on U-100 syringe |
| 250 mcg (Standard Daily Target) | 0.050 mL | 5 Units 5.0 units (0.05 mL) on U-100 syringe |
| 500 mcg (Intensive Repair Target) | 0.10 mL | 10 Units 10.0 units (0.10 mL) on U-100 syringe |
| 750 mcg (Acute Trauma Ceiling) | 0.15 mL | 15 Units 15.0 units (0.15 mL) on U-100 syringe |
| Research Dose | Calibrated Volume | U-100 Syringe Units | Graduation Description |
|---|---|---|---|
| 100 mcg (Micro Calibration) | 0.04 mL (40 µL) | 4 Units | 2.0 units (0.02 mL) on U-100 syringe |
| 250 mcg (Standard Daily Target) | 0.1 mL (100 µL) | 10 Units | 5.0 units (0.05 mL) on U-100 syringe |
| 500 mcg (Intensive Repair Target) | 0.2 mL (200 µL) | 20 Units | 10.0 units (0.10 mL) on U-100 syringe |
| 750 mcg (Acute Trauma Ceiling) | 0.3 mL (300 µL) | 30 Units | 15.0 units (0.15 mL) on U-100 syringe |
ISO 8537 Sterile Insulin Syringe Standard · Optical Meniscus Resolution & Volumetric Parallax Engineering
Detachable needles leave significant fluid trapped in the plastic hub collar. In peptide protocols, this causes substantial loss of active ingredient per administration.
| Barrel Capacity | Graduation Interval | Volume per Tick | Hub Dead-Space | Needle Spec | Suitability for 2 Units |
|---|---|---|---|---|---|
| 0.3 mL (30 Units)BEST FIT | 0.5 Unit | 5 µL (0.005 mL) | < 0.4 µL | 31G × 5/16" (8mm) Integrated Ultra-Fine | ✓ Accommodates 2 units |
| 0.5 mL (50 Units) | 1 Unit | 10 µL (0.010 mL) | < 0.8 µL | 30G–31G × 5/16" (8mm) Integrated | ✓ Accommodates 2 units |
| 1 mL (100 Units) | 2 Unit | 20 µL (0.020 mL) | < 2.1 µL | 29G–30G × 1/2" (12.7mm) Integrated | ✓ Accommodates 2 units |
Viewing the syringe from an angle introduces a 1.0–2.5 unit parallax error. Always raise the barrel to direct eye level against a high-contrast white background. Align the front edge of the top black plunger seal ring with the target line.
Standard 5/16" (8mm) laboratory dispensing needles are calibrated for direct 90° fluid transfer into target analytical matrix vials. If utilizing 1/2" (12.7mm) cannulas in deep laboratory vessels, introduce at a 45° angle to avoid contact with vessel sidewalls.
Stoichiometric supply planning, sequential reconstitution cadence, and itemized consumables BOM for BPC-157.
Do NOT reconstitute all 16 vials simultaneously. Reconstitute one vial at a time as the active protocol requires. Once reconstituted with Bacteriostatic Water USP, a vial maintains stability for 28 days at +2°C to +8°C. Remaining unopened vials should be preserved in solid lyophilized cake form at -20°C to prevent hydrolysis and oxidation.
| Week | Study / Assay Phase | Weekly Target Dose | Syringe Draw (U-100) | Active Vial # | Cumulative Active Mass |
|---|---|---|---|---|---|
| Week 1 | Phase 3: Extracellular Matrix Consolidation & Washout (Week 6+) | 1.0 mg(7x/wk) | 40 Units(0.40 mL) | Vial #2(0mg rem) | 7.0 mg / 70.0 mg |
| Week 2 | Phase 2: Active Tissue Regeneration Block (Weeks 2–5) | 500 mcg(7x/wk) | 20 Units(0.20 mL) | Vial #3(1.5mg rem) | 10.5 mg / 70.0 mg |
| Week 3 | Phase 2: Active Tissue Regeneration Block (Weeks 2–5) | 500 mcg(7x/wk) | 20 Units(0.20 mL) | Vial #4(1.5mg rem) | 14.0 mg / 70.0 mg |
| Week 4 | Phase 2: Active Tissue Regeneration Block (Weeks 2–5) | 500 mcg(7x/wk) | 20 Units(0.20 mL) | Vial #5(1.5mg rem) | 17.5 mg / 70.0 mg |
| Week 5 | Phase 2: Active Tissue Regeneration Block (Weeks 2–5) | 500 mcg(7x/wk) | 20 Units(0.20 mL) | Vial #6(1.5mg rem) | 21.0 mg / 70.0 mg |
| Week 6 | Phase 3: Extracellular Matrix Consolidation & Washout (Week 6+) | 1.0 mg(7x/wk) | 40 Units(0.40 mL) | Vial #7(0mg rem) | 28.0 mg / 70.0 mg |
| Week 7 | Phase 3: Extracellular Matrix Consolidation & Washout (Week 6+) | 1.0 mg(7x/wk) | 40 Units(0.40 mL) | Vial #8(0mg rem) | 35.0 mg / 70.0 mg |
| Week 8 | Phase 3: Extracellular Matrix Consolidation & Washout (Week 6+) | 1.0 mg(7x/wk) | 40 Units(0.40 mL) | Vial #9(0mg rem) | 42.0 mg / 70.0 mg |
| Week 9 | Phase 3: Extracellular Matrix Consolidation & Washout (Week 6+) | 1.0 mg(7x/wk) | 40 Units(0.40 mL) | Vial #10(0mg rem) | 49.0 mg / 70.0 mg |
| Week 10 | Phase 3: Extracellular Matrix Consolidation & Washout (Week 6+) | 1.0 mg(7x/wk) | 40 Units(0.40 mL) | Vial #11(0mg rem) | 56.0 mg / 70.0 mg |
| Week 11 | Phase 3: Extracellular Matrix Consolidation & Washout (Week 6+) | 1.0 mg(7x/wk) | 40 Units(0.40 mL) | Vial #12(0mg rem) | 63.0 mg / 70.0 mg |
| Week 12 | Phase 3: Extracellular Matrix Consolidation & Washout (Week 6+) | 1.0 mg(7x/wk) | 40 Units(0.40 mL) | Vial #13(0mg rem) | 70.0 mg / 70.0 mg |
Study duration: 4 to 6 Weeks per analytical research block · Washout: 2 to 4 Weeks between experimental cycles
| Period / Phase | Target Amount | Frequency | Notes & Calibration |
|---|---|---|---|
| Days 1–7Starting Baseline | 250 mcg | 1x Daily (Morning SubQ) | Phase 1: Initial Micro-Dose Calibration: Baseline tissue tolerance, receptor saturation & local microvascular angiogenesis (5.0 units (0.05 mL) on U-100 syringe at 5.0 mg/mL concentration) |
| Weeks 2–5 | 500 mcg | 1x Daily or 250 mcg Twice Daily | Phase 2: Active Tissue Regeneration Block: Accelerated collagen type I fibril deposition, tendon fibroblast outgrowth, and eNOS stimulation (10.0 units (0.10 mL) on U-100 syringe once daily (or 5.0 units BID)) |
| Week 6+ | Observation Period | Zero dosing | Phase 3: Extracellular Matrix Consolidation & Washout: Systemic receptor reset and persistent collagen bundle cross-linking observation (2–4 week cessation to observe persistent cellular healing dynamics) |
4-phase stability timeline, RP-HPLC degradation benchmarks, and storage SOPs for BPC-157
Operating Window: +2°C to +8°C (36°F to 46°F)
Active working solution dissolved in Bacteriostatic Water USP (0.9% Benzyl Alcohol).
| Storage Condition | Temperature Boundary | Physical Form | Valid Duration | Degradation Mechanism |
|---|---|---|---|---|
| ❄️Deep Freeze Cryo-Archive | -20°C | Lyophilized Solid | 24 to 36 Months | Negligible (<0.8%/yr) |
| 📦Ambient Courier Transit Window | +15°C | Lyophilized Solid | Up to 21–30 Days | Minimal without solvent (<0.5%) |
| 💧Reconstituted Refrigerated Storage (2°C–8°C) | +2°C | Reconstituted Solution | 28 to 35 Days | Gradual deamidation >28 days |
| 🚫Critical Degradation Thresholds | >37°C | Degradation Hazard | Immediate Degradation Hazard | Rapid peptide cleavage & aggregation |
Direct the needle bevel gently against the inside glass vial wall. Allow the vacuum to smoothly draw diluent into the vial without vigorous bubbling. Swirl in a continuous horizontal circular motion for 45–60 seconds. Do not invert or shake to prevent peptide shearing.
BPC-157 displays an estimated half-life of ~4–6 Hours (Systemic peptide stability; localized extracellular retention ~24h). Typical study protocols run for 4 to 6 Weeks per analytical research block followed by a washout period of 2 to 4 Weeks between experimental cycles.
High-purity lyophilized laboratory reference formulation with certified Certificate of Analysis (COA).
Standard Lyophilized Monograph
Gastric Pentadecapeptide Laboratory Protocol & In-Vitro Angiogenesis Standard. Formulated for in-vitro research and laboratory analytical validation.
Store desiccated at -20°C upon receipt. Reconstitute strictly in a certified laminar airflow hood utilizing sterile disposable instruments. Avoid direct exposure to UV or fluorescent radiation.
| Net Active Mass | Target Solvent | Diluent Volume | Resulting Concentration | Syringe Graduation Scale |
|---|---|---|---|---|
| 10 mg Lyophilized Cake | Bacteriostatic Water USP (0.9% Benzyl Alcohol) | 2.0 mL | 5.00 mg/mL | 1 Unit = 50.0 mcg (0.01 mL) |
Swab vial septum with sterile 70% IPA pad. Inspect cake for vacuum seal integrity.
Introduce 2.0 mL solvent slowly down inner glass wall. Never spray directly on cake.
Swirl gently in horizontal circles until fully dissolved. Never shake or invert aggressively.
Rest at +2°C to +8°C for 10 minutes until solution is crystal clear before drawing.
| Phase | Target Active Dose | U-100 Syringe Graduation | Cadence & Pharmacological Purpose |
|---|---|---|---|
| Days 1–7 (Priming) | 250 mcg | 5.0 Units (0.050 mL) | Initial receptor priming; evaluate baseline physiological tolerance. |
| Weeks 2–4 (Saturation) | 375 mcg | 7.5 Units (0.075 mL) | Target assay maintenance; peak neurotrophic / metabolic response. |
| Weeks 5–6 (Taper & Washout) | 250 mcg | 5.0 Units (0.050 mL) | Receptor consolidation prior to mandatory 4-week washout cycle. |
RP-HPLC / LC-MS In-Vitro Assay
Purity Spec: ≥ 98.0% Area
Research Use Only (RUO)
NOT EVALUATED OR APPROVED BY FDA